Ultrastructural changes in psoriatic epidermis following anthralin treatment.
D000328:Adult; D000873:Anthracenes / Q000627:therapeutic use*; D000875:Anthralin / Q000627:therapeutic use*; D001485:Basement Membrane / Q000473:pathology; D002462:Cell Membrane / Q000473:pathology; D003594:Cytoplasmic Granules / Q000473:pathology; D005260:Female; D006801:Humans; D002479:Inclusion Bodies / Q000473:pathology; D007365:Intercellular Junctions / Q000473:pathology; D008297:Male; D009824:Ointments; D011565:Psoriasis / Q000188:drug therapy / Q000473:pathology*; D012867:Skin / Q000187:drug effects* / Q000473:pathology; D013997:Time Factors; D014945:Wound Healing
D000873:Anthracenes; D009824:Ointments; D000875:Anthralin